Table 1.
Serum uric acid concentration and prostate cancer risk, 6,574 men in the ARIC study, 1987–2012
| Overall | White men | Black men | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Person-years | HR* | (95%CI) | Person-years | HR | (95%CI) | Person-years | HR | (95%CI) | |
| Quartiles** | |||||||||
| 1st (< 5mg/dL) | 29,629 | 1 | (Ref) | 23,783 | 1 | (Ref) | 5,847 | 1 | (Ref) |
| 2nd (5.0–5.7 mg/dL) | 30,604 | 0.92 | (0.75–1.11) | 25,133 | 1.00 | (0.80–1.26) | 5,471 | 0.73 | (0.50–1.06) |
| 3rd (5.8–6.7 mg/dL) | 31,348 | 0.89 | (0.73–1.08) | 25,328 | 0.90 | (0.71–1.14) | 6,020 | 0.85 | (0.59–1.21) |
| 4th (≥ 6.8 mg/dL) | 27,393 | 0.89 | (0.73–1.10) | 19,616 | 0.89 | (0.68–1.15) | 7,776 | 0.86 | (0.61–1.22) |
| P-trend | 0.3 | 0.2 | 0.7 | ||||||
| Quartiles collapsed | |||||||||
| 1st (< 5mg/dL) | 29,629 | 1 | (Ref) | 23.783 | 1 | (Ref) | 5,847 | 1 | (Ref) |
| 2nd–4th (≥ 5.0 mg/dL) | 89,345 | 0.90 | (0.76–1.06) | 70,076 | 0.94 | (0.77–1.14) | 19,269 | 0.82 | (0.61–1.09) |
| Uric acid cutpoint | |||||||||
| Normal (< 7 mg/dL) | 95,621 | 1 | (Ref) | 77,345 | 1 | (Ref) | 18,275 | 1 | (Ref) |
| Hyperuricemia (≥ 7 mg/dL) | 23,354 | 0.94 | (0.79–1.12) | 16,513 | 0.89 | (0.70–1.12) | 6,840 | 1.01 | (0.77–1.34) |
Model adjusted for age (continuous), joint race by center (White from Minnesota; White from Washington Co. or Forsyth Co.; Black from Jackson; Black from Washington Co. or Forsyth Co.), education (<high school, high school with some college, college graduate), height (continuous), updated body mass index (BMI, kg/m2, continuous), updated cigarette smoking status (current/former smoker who quit <10 years ago; former smoker who quit ≥10 years ago, never smoker), updated diabetes status (no diabetes, pre-diabetes, undiagnosed diabetes, diagnosed diabetes), updated aspirin use, and updated statin use.
Serum uric acid was available at visits 1 and 2 and were updated in the model. Quartiles based on visit 1 serum uric acid concentration distribution